Search - tctmd.com

Displaying 21 - 40 of 81

Sort: Relevancy | Date

News Daily News

Upstream Bivalirudin Best in NSTE-ACS Patients With Planned Invasive Strategy

L.A. McKeown

September 21, 2015

News Industry News

Medicure Announces Filing of sNDA for New AGGRASTAT® Indication

September 10, 2015

News Conference News ESC 2015

MATRIX Antithrombin: Bivalirudin Fails to Reduce Net Adverse Events vs Heparin in ACS Patients Undergoing PCI

Yael L. Maxwell

September 02, 2015

News Industry News

Cardiome Submits Supplemental New Drug Submission (sNDS) For AGGRASTAT To Health Canada

July 22, 2015

News Industry News

Hospira Announces U.S. Launch of Generic Bivalirudin for Injection

July 16, 2015

News Industry News

The Medicines Company Authorizes Generic Launch of ANGIOMAX® (bivalirudin)

July 09, 2015

News Daily News

Bivalirudin Plus GPI Cuts Bleeding, Mortality in Heart Failure Patients Undergoing PCI

June 09, 2015

News Daily News

Activated Clotting Time May Predict Ischemic Events in PCI Patients on Heparin Alone

L.A. McKeown

April 28, 2015

News Conference News ACC 2015

MATRIX Provides Support for Radial Access, Mixed Results for Bivalirudin

Todd Neale

March 17, 2015

News Daily News

Tanto una Dosis Segura como el Uso basado en las Directrices de los Antitrombóticos se asocia a los Resultados del SCASEST

Yael L. Maxwell

March 04, 2015

News Daily News

Both Dosing Safety, Guideline-Based Use of Antithrombotics Related to NSTE-ACS Outcomes

Yael L. Maxwell

March 04, 2015

News Daily News

Outcomes Do Not Suffer With Shortened Eptifibatide Infusion During PCI

Todd Neale

January 28, 2015

News Daily News

患者级的集合分析表明，可以在直接PCI中使用比伐卢定

Yael L. Maxwell

January 12, 2015

News Daily News

Un Análisis Conjunto a Nivel del Paciente Avala el Uso de Bivalirudina en PCI Primarias

Yael L. Maxwell

January 12, 2015

News Daily News

Patient-Level Pooled Analysis Supports Bivalirudin Use in Primary PCI

Yael L. Maxwell

January 12, 2015

News Conference News TCT 2014

EUROMAX Substudy: Bivalirudin Noninferior to Heparin Plus GPI for Myocardial Reperfusion

September 14, 2014

Presentation TCT 2014

Antithrombin Therapy and GP IIb/IIIa Inhibitors in Patients with ACS and in Those Undergoing PCI

Presenter: Frederick Feit, Sripal Bangalore

September 13, 2014

Presentation TCT 2014

Are GP IIb/IIIa Inhibitors Still Useful?

Presenter: Marco Valgimigli

September 13, 2014

News Conference News TCT 2014

Meta-analysis: Less Bleeding, More Stent Thrombosis with Bivalirudin vs. Heparin After PCI

September 13, 2014

News Daily News

Meta-Analysis: Worse Clinical Outcomes But Less Bleeding With Bivalirudin in PCI

Todd Neale

August 20, 2014

Advertisement

Upstream Bivalirudin Best in NSTE-ACS Patients With Planned Invasive Strategy

Medicure Announces Filing of sNDA for New AGGRASTAT® Indication

MATRIX Antithrombin: Bivalirudin Fails to Reduce Net Adverse Events vs Heparin in ACS Patients Undergoing PCI

Cardiome Submits Supplemental New Drug Submission (sNDS) For AGGRASTAT To Health Canada

Hospira Announces U.S. Launch of Generic Bivalirudin for Injection

The Medicines Company Authorizes Generic Launch of ANGIOMAX® (bivalirudin)

Bivalirudin Plus GPI Cuts Bleeding, Mortality in Heart Failure Patients Undergoing PCI

Activated Clotting Time May Predict Ischemic Events in PCI Patients on Heparin Alone

MATRIX Provides Support for Radial Access, Mixed Results for Bivalirudin

Tanto una Dosis Segura como el Uso basado en las Directrices de los Antitrombóticos se asocia a los Resultados del SCASEST

Both Dosing Safety, Guideline-Based Use of Antithrombotics Related to NSTE-ACS Outcomes

Outcomes Do Not Suffer With Shortened Eptifibatide Infusion During PCI

患者级的集合分析表明，可以在直接PCI中使用比伐卢定

Un Análisis Conjunto a Nivel del Paciente Avala el Uso de Bivalirudina en PCI Primarias

Patient-Level Pooled Analysis Supports Bivalirudin Use in Primary PCI

EUROMAX Substudy: Bivalirudin Noninferior to Heparin Plus GPI for Myocardial Reperfusion

Antithrombin Therapy and GP IIb/IIIa Inhibitors in Patients with ACS and in Those Undergoing PCI

Are GP IIb/IIIa Inhibitors Still Useful?

Meta-analysis: Less Bleeding, More Stent Thrombosis with Bivalirudin vs. Heparin After PCI

Meta-Analysis: Worse Clinical Outcomes But Less Bleeding With Bivalirudin in PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content